Kymera Therapeutics presented new preclinical data for KT-579, an oral IRF5 degrader, showing it effectively modulates multiple inflammatory pathways in inflammatory bowel disease (IBD) models. KT-579 demonstrated comparable or superior activity to existing therapies by reducing key inflammatory cytokines and improving disease markers. The drug is currently in a Phase 1 trial with healthy volunteers, focusing on safety and IRF5 degradation, with results expected in the second half of 2026. This novel oral treatment could offer a new option for patients with complex autoimmune diseases like IBD.
Century Aluminum Company announced it will report its second quarter 2026 earnings on August 6, 2026, after the market closes. The company will also host a live conference call at 5:00 p.m. Eastern time the same day, accessible via its website. This ...
Blue Gold Limited was notified by Nasdaq that it does not meet the minimum Market Value of Publicly Held Shares (MVPHS) requirement of $15 million, based on market values from June 10 to July 23, 2026. The company has 180 days, until January 20, 2027...
Sun Communities reported a strong Core Funds from Operations (FFO) of $1.84 per share for Q2 2026, surpassing its guidance range of $1.71 to $1.79. However, the company posted a net loss of $8.08 per diluted share, mainly due to losses from discontin...
T3 Defense's stock soared 201% following its subsidiary's expansion of defense technology into industrial materials, signaling strong growth potential. NextCure saw a 20.75% rise driven by a significant short squeeze, reflecting heavy short interest ...
Environics Analytics has named Cenker Ozhelvaci as Head of Sales for its core direct sales teams. Ozhelvaci brings extensive experience from sectors like financial services and technology, having previously led sales at Provenir and Amazon Canada. Hi...
